FDA re­jects Ver­ri­ca’s skin warts pitch, a month af­ter flag­ging ap­pli­ca­tion ‘de­fi­cien­cies’

Two years ago, Ver­ri­ca Phar­ma land­ed a $75 mil­lion IPO on the promise they could de­vel­op the first ever-FDA ap­proved drug for mol­lus­cum con­ta­gio­sum, an in­fec­tion that caus­es warts. Now that won’t hap­pen, at least not this sum­mer.

The FDA to­day re­ject­ed Ver­ri­ca’s ap­pli­ca­tion to have their lead top­i­cal drug VP-102 ap­proved for mol­lus­cum con­ta­gio­sum. The news like­ly came as lit­tle sur­prise to Ver­ri­ca or its in­vestors; the biotech dis­closed in late June that the FDA sent a let­ter say­ing “de­fi­cien­cies” in their ap­pli­ca­tion pre­clud­ed a dis­cus­sion around la­bel­ing or post-mar­ket­ing com­mit­ments.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.